Recent advances in co-amorphous drug formulations

Aaltonen, 2009, Towards physico-relevant dissolution testing: the importance of solid-state analysis in dissolution, Dissolut. Technol., 16, 47, 10.14227/DT160209P47 Hancock, 1997, Characteristics and significance of the amorphous state in pharmaceutical systems, J. Pharm. Sci., 86, 1, 10.1021/js9601896 Chiou, 1971, Pharmaceutical applications of solid dispersion systems, J. Pharm. Sci., 60, 1281, 10.1002/jps.2600600902 Laitinen, 2014, Theoretical considerations in developing amorphous solid dispersions, 35 Vaka, 2014, Excipients for amorphous solid dispersions, 123 Van den Mooter, 2012, The use of amorphous solid dispersions: a formulation strategy to overcome poor solubility and dissolution rate, 9, e79 Marsac, 2006, Theoretical and practical approaches for prediction of drug–polymer miscibility and solubility, Pharm. Res., 23, 2417, 10.1007/s11095-006-9063-9 Leuner, 2000, Improving drug solubility for oral delivery using solid dispersions, Eur. J. Pharm. Biopharm., 50, 47, 10.1016/S0939-6411(00)00076-X Hancock, 1995, Molecular mobility of amorphous pharmaceutical solids below their glass transition temperatures, Pharm. Res., 12, 799, 10.1023/A:1016292416526 Janssens, 2009, Review: physical chemistry of solid dispersions, J. Pharm. Pharmacol., 61, 1571, 10.1211/jpp.61.12.0001 Lu, 1998, Phase behavior of binary and ternary amorphous mixtures containing indomethacin, citric acid, and PVP, Pharm. Res., 15, 1202, 10.1023/A:1011983606606 Serajuddin, 1999, Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs, J. Pharm. Sci., 88, 1058, 10.1021/js980403l Vasconcelos, 2007, Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs, Drug Discov. Today, 12, 1068, 10.1016/j.drudis.2007.09.005 Brown, 2014, Hot-melt extrusion for solid dispersions: composition and design considerations, 197 Choudhari, 2014, Mesoporous silica drug delivery systems, 665 Wang, 2010, Oxidized mesoporous silicon microparticles for improved oral delivery of poorly soluble drugs, Mol. Pharm., 7, 227, 10.1021/mp900221e Song, 2005, Functionalized SBA-15 materials as carriers for controlled drug delivery: influence of surface properties on matrix−drug interactions, Langmuir, 21, 9568, 10.1021/la051167e Qian, 2011, Application of mesoporous silicon dioxide and silicate in oral amorphous drug delivery system, J. Pharm. Sci., 101, 444, 10.1002/jps.22779 Prestidge, 2007, Mesoporous silicon: a platform for the delivery of therapeutics, Expert Opin. Drug Deliv., 4, 101, 10.1517/17425247.4.2.101 Laitinen, 2013, Emerging trends in the stabilization of amorphous drugs, Int. J. Pharm., 453, 65, 10.1016/j.ijpharm.2012.04.066 Löbmann, 2014, Stabilized amorphous solid dispersions with small molecule excipients, 613 Chieng, 2009, Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation, Eur. J. Pharm. Biopharm., 71, 47, 10.1016/j.ejpb.2008.06.022 Bates, 2006, Analysis of amorphous and nanocrystalline solids from their X-ray diffraction patterns, Pharm. Res., 23, 2333, 10.1007/s11095-006-9086-2 Rades, 2013, Molecular structure, properties, and states of matter, 541 Craig, 1999, The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems, Int. J. Pharm., 179, 179, 10.1016/S0378-5173(98)00338-X Sandhu, 2014, Overview of amorphous solid dispersion technologies, 91 Fukuoka, 1989, Glassy state of pharmaceuticals. III.: thermal properties and stability of glassy pharmaceuticals and their binary glass systems, Chem. Pharm. Bull., 37, 1047, 10.1248/cpb.37.1047 Martínez, 2014, Stabilization of amorphous paracetamol based systems using traditional and novel strategies, Int. J. Pharm., 477, 294, 10.1016/j.ijpharm.2014.10.021 Johari, 2010, Dielectric study of equimolar acetaminophen–aspirin, acetaminophen–quinidine, and benzoic acid–progesterone molecular alloys in the glass and ultraviscous states and their relevance to solubility and stability, J. Pharm. Sci., 99, 1358, 10.1002/jps.21930 Hoppu, 2007, Characterisation of blends of paracetamol and citric acid, J. Pharm. Pharmacol., 59, 373, 10.1211/jpp.59.3.0006 Hoppu, 2009, Rheology and molecular mobility of amorphous blends of citric acid and paracetamol, Eur. J. Pharm. Biopharm., 71, 55, 10.1016/j.ejpb.2008.06.029 Schantz, 2009, A solid-state NMR study of phase structure, molecular interactions, and mobility in blends of citric acid and paracetamol, J. Pharm. Sci., 98, 1862, 10.1002/jps.21559 Shimada, 2013, Features of heat-induced amorphous complex between indomethacin and lidocaine, Colloids Surf. B: Biointerfaces, 102, 590, 10.1016/j.colsurfb.2012.08.060 Shimada, 2013, Characteristics of amorphous complex formed between indomethacin and lidocaine hydrochloride, Colloids Surf. B: Biointerfaces, 105, 98, 10.1016/j.colsurfb.2012.12.026 Pajula, 2014, Phase separation in coamorphous systems: in silico prediction and the experimental challenge of detection, Mol. Pharm., 11, 2271, 10.1021/mp400712m Löbmann, 2011, Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen, Mol. Pharm., 8, 1919, 10.1021/mp2002973 Löbmann, 2013, A theoretical and spectroscopic study of co-amorphous naproxen and indomethacin, Int. J. Pharm., 453, 80, 10.1016/j.ijpharm.2012.05.016 Yamamura, 2002, Physicochemical properties of amorphous salt of cimetidine and diflunisal system, Int. J. Pharm., 241, 213, 10.1016/S0378-5173(02)00195-3 Yamamura, 2000, Physicochemical properties of amorphous precipitates of cimetidine–indomethacin binary system, Eur. J. Pharm. Biopharm., 49, 259, 10.1016/S0939-6411(00)00060-6 Shayanfar, 2013, Drug–drug coamorphous systems: characterization and physicochemical properties of Coamorphous atorvastatin with carvedilol and glibenclamide, J. Pharm. Innov., 8, 218, 10.1007/s12247-013-9162-1 Masuda, 2012, Cocrystallization and amorphization induced by drug–excipient interaction improves the physical properties of acyclovir, Int. J. Pharm., 422, 160, 10.1016/j.ijpharm.2011.10.046 Tantishaiyakul, 2010, Characterization of cimetidine–piroxicam coprecipitate interaction using experimental studies and molecular dynamic simulations, AAPS PharmSciTech, 11, 952, 10.1208/s12249-010-9461-5 Gao, 2013, Coamorphous repaglinide–saccharin with enhanced dissolution, Int. J. Pharm., 450, 290, 10.1016/j.ijpharm.2013.04.032 Suresh, 2014, A novel curcumin–artemisin coamorphous solid: physical properties and pharmacokinetic profile, RCS Adv., 4, 58357 Dengale, 2014, Preparation and characterization of co-amorphous ritonavir–indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions, Eur. J. Pharm. Sci., 62, 57, 10.1016/j.ejps.2014.05.015 Dengale, 2015, Fabrication, solid state characterization and bioavailability assessment of stable binary amorphous phases of ritonavir with quercetin, Eur. J. Pharm. Biopharm., 89, 329, 10.1016/j.ejpb.2014.12.025 Qian, 2015, Coamorphous lurasidone hydrochloride–saccharin with charge-assisted hydrogen bonding interaction shows improved physical stability and enhanced dissolution with pH-independent solubility behavior, Cryst. Growth Des., 15, 2920, 10.1021/acs.cgd.5b00349 Descamps, 2007, Transformation of pharmaceutical compounds upon milling and comilling: the role of Tg, J. Pharm. Sci., 96, 1398, 10.1002/jps.20939 Hu, 2014, Mechanochemical reaction of sulfathiazole with carboxylic acids: formation of a cocrystal, a salt, and coamorphous solids, Cryst. Growth Des., 14, 803, 10.1021/cg401673z Löbmann, 2012, Co-amorphous simvastatin and glipizide combinations show improved physical stability without evidence of intermolecular interactions, Eur. J. Pharm. Biopharm., 81, 159, 10.1016/j.ejpb.2012.02.004 Löbmann, 2013, Amino acids as co-amorphous stabilizers for poorly water soluble drugs — part 1: preparation, stability and dissolution enhancement, Eur. J. Pharm. Biopharm., 85, 873, 10.1016/j.ejpb.2013.03.014 Jensen, 2014, Improving co-amorphous drug formulations by the addition of the highly water soluble amino acid proline, Pharmaceutics, 6, 416, 10.3390/pharmaceutics6030416 Löbmann, 2013, Amino acids as co-amorphous stabilizers for poorly water-soluble drugs — part 2: molecular interactions, Eur. J. Pharm. Biopharm., 85, 882, 10.1016/j.ejpb.2013.03.026 Laitinen, 2014, Amino acids as co-amorphous excipients for simvastatin and glibenclamide: physical properties and stability, Mol. Pharm., 11, 2381, 10.1021/mp500107s Heikkinen, 2015, Dissolution properties of co-amorphous drug–amino acid formulations in buffer and biorelevant media, Pharmazie, 70, 452 Jensen, 2015, Formation mechanism of coamorphous drug–amino acid mixtures, Mol. Pharm., 12, 2484, 10.1021/acs.molpharmaceut.5b00295 Allesø, 2009, Enhanced dissolution rate and synchronized release of drugs in binary systems through formulation: amorphous naproxen–cimetidine mixtures prepared by mechanical activation, J. Control. Release, 136, 45, 10.1016/j.jconrel.2009.01.027 Lenz, 2015, Solid-state properties and dissolution behaviour of tablets containing co-amorphous indomethacin–arginine, Eur. J. Pharm. Biopharm., 96, 44, 10.1016/j.ejpb.2015.07.011 Shamblin, 1998, Mixing behavior of colyophylized binary systems, J. Pharm. Sci., 87, 694, 10.1021/JS9704801 Hoppu, 2009, New processing technique for viscous amorphous materials and characterisation of their stickiness and deformability, Eur. J. Pharm. Biopharm., 72, 183, 10.1016/j.ejpb.2008.11.007 Hoppu, 2009, Characterization of ultrasound extrudated and cut citric acid/paracetamol blends, J. Pharm. Sci., 98, 2140, 10.1002/jps.21577 Wickström, 2015, Improvement of dissolution rate of indomethacin by inkjet printing, Eur. J. Pharm. Sci., 75, 91, 10.1016/j.ejps.2015.03.009 Marsac, 2009, Estimation of drug–polymer miscibility and solubility in amorphous solid dispersions using experimentally determined interaction parameters, Pharm. Res., 26, 139, 10.1007/s11095-008-9721-1 Baird, 2012, Evaluation of amorphous solid dispersion properties using thermal analysis techniques, Adv. Drug Deliv. Rev., 64, 396, 10.1016/j.addr.2011.07.009 Kawakami, 2012, Modification of physicochemical characteristics of active pharmaceutical ingredients and application of supersaturatable dosage forms for improving bioavailability of poorly absorbed drugs, Adv. Drug Deliv. Rev., 64, 480, 10.1016/j.addr.2011.10.009 Yu, 2001, Amorphous pharmaceutical solids: preparation, characterization and stabilization, Adv. Drug Deliv. Rev., 48, 27, 10.1016/S0169-409X(01)00098-9 van Drooge, 2006, Characterization of the molecular distribution of drugs in glassy solid dispersions at the nano-meter scale, using differential scanning calorimetry and gravimetric water vapour sorption techniques, Int. J. Pharm., 310, 220, 10.1016/j.ijpharm.2005.12.007 Knopp, 2015, Comparative study of different methods for the prediction of drug–polymer solubility, Mol. Pharm., 12, 3408, 10.1021/acs.molpharmaceut.5b00423 Shamblin, 1999, Characterization of the time scales of molecular motion in pharmaceutically important glasses, J. Phys. Chem. B, 103, 4113, 10.1021/jp983964+ Jensen, 2015, Preparation and characterization of spray-dried co-amorphous drug–amino acid salts, J. Pharm. Pharmacol. Teja, 2015, Simultaneous improvement of solubility and permeability by fabricating binary glassy materials of Talinolol with Naringin: Solid state characterization, in-vivo in-situ evaluation, Eur. J. Pharm. Sci., 78, 234, 10.1016/j.ejps.2015.08.002 Brostow, 2008, Prediction of glass transition temperatures: binary blends and copolymers, Mater. Lett., 62, 3152, 10.1016/j.matlet.2008.02.008 Moynihan, 1993, Correlation between the width of the glass transition region and the temperature dependence of the viscosity of high-Tg glasses, J. Am. Ceram. Soc., 76, 1081, 10.1111/j.1151-2916.1993.tb03724.x Painter, 1991, Effect of hydrogen bonding on the enthalpy of mixing and the composition dependence of the glass transition temperature in polymer blends, Macromolecules, 24, 5630, 10.1021/ma00020a023 Lu, 1992, Relationship between the glass transition temperature and the interaction parameter of miscible binary polymer blends, Macromolecules, 25, 3242, 10.1021/ma00038a033 Alonzo, 2010, Understanding the behavior of amorphous pharmaceutical systems during dissolution, Pharm. Res., 27, 608, 10.1007/s11095-009-0021-1 Lipinski, 2000, Drug-like properties and the causes of poor solubility and poor permeability, J. Pharmacol. Toxicol. Methods, 44, 235, 10.1016/S1056-8719(00)00107-6 Wagner, 2001, Intestinal drug efflux: formulation and food effects, Adv. Drug Deliv. Rev., 50, S13, 10.1016/S0169-409X(01)00183-1 Akbuga, 1988, Preparation and properties of tablets prepared from furosemide-PVP solid dispersion systems, Drug Dev. Ind. Pharm., 14, 2091, 10.3109/03639048809152004 Owusu-Ababio, 1998, Comparative dissolution studies for mefenamic acid-polyethylene glycol solid dispersion systems and tablets, Pharm. Dev. Technol., 3, 405, 10.3109/10837459809009868